| Cancer DNA methylation: molecular mechanisms and clinical implications MT McCabe, JC Brandes, PM Vertino Clinical Cancer Research 15 (12), 3927-3937, 2009 | 367 | 2009 |
| Functional properties of CD4+ CD28− T cells in the aging immune system CM Weyand, JC Brandes, D Schmidt, JW Fulbright, JJ Goronzy Mechanisms of ageing and development 102 (2-3), 131-147, 1998 | 235 | 1998 |
| Modulation of CD28 expression: distinct regulatory pathways during activation and replicative senescence AN Vallejo, JC Brandes, CM Weyand, JJ Goronzy The Journal of Immunology 162 (11), 6572-6579, 1999 | 219 | 1999 |
| Enhanced anti-tumor activity by the combination of the natural compounds (−)-epigallocatechin-3-gallate and luteolin: potential role of p53 ARMR Amin, D Wang, H Zhang, S Peng, HJC Shin, JC Brandes, ... Journal of biological chemistry 285 (45), 34557-34565, 2010 | 135 | 2010 |
| CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype JC Brandes, M Van Engeland, KAD Wouters, MP Weijenberg, JG Herman Carcinogenesis 26 (6), 1152-1156, 2005 | 101 | 2005 |
| Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter JC Brandes, H Carraway, JG Herman Oncogene 26 (42), 6229-6237, 2007 | 95 | 2007 |
| Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies DM Shin, H Zhang, NF Saba, AY Chen, S Nannapaneni, ARMR Amin, ... Clinical Cancer Research 19 (5), 1244-1256, 2013 | 72 | 2013 |
| Could valproic acid be an effective anticancer agent? The evidence so far SA Brodie, JC Brandes Expert review of anticancer therapy 14 (10), 1097-1100, 2014 | 66 | 2014 |
| Class I HDACs Are Mediators of Smoke Carcinogen–Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer SA Brodie, G Li, A El-Kommos, H Kang, SS Ramalingam, M Behera, ... Cancer prevention research 7 (3), 351-361, 2014 | 46 | 2014 |
| Human immunodeficiency virus‐associated lung cancer in the era of highly active antiretroviral therapy S Pakkala, Z Chen, D Rimland, TK Owonikoko, C Gunthel, JR Brandes, ... Cancer 118 (1), 164-172, 2012 | 45 | 2012 |
| Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine S Derks, AHG Cleven, V Melotte, KM Smits, JC Brandes, N Azad, ... Cancer and Metastasis Reviews 33, 161-171, 2014 | 44 | 2014 |
| Real‐World Effectiveness of Systemic Agents Approved for Advanced Non‐Small Cell Lung Cancer: A SEER–Medicare Analysis TK Owonikoko, C Ragin, Z Chen, S Kim, M Behera, JC Brandes, NF Saba, ... The oncologist 18 (5), 600-610, 2013 | 39 | 2013 |
| Long‐term use of valproic acid in US veterans is associated with a reduced risk of smoking‐related cases of head and neck cancer H Kang, TW Gillespie, M Goodman, SA Brodie, M Brandes, M Ribeiro, ... Cancer 120 (9), 1394-1400, 2014 | 37 | 2014 |
| Following mitochondrial footprints through a long mucosal path to lung cancer S Dasgupta, RC Yung, WH Westra, DA Rini, J Brandes, D Sidransky PloS one 4 (8), e6533, 2009 | 35 | 2009 |
| Occlusive endobronchial stent placement as a novel management approach to massive hemoptysis from lung cancer JC Brandes, E Schmidt, R Yung Journal of Thoracic Oncology 3 (9), 1071-1072, 2008 | 32 | 2008 |
| Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature JC Brandes, SA Grossman, H Ahmad Cancer investigation 24 (3), 283-287, 2006 | 27 | 2006 |
| CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC RN Pillai, SA Brodie, GL Sica, Y Shaojin, G Li, DC Nickleach, L Yuan, ... Clinical Cancer Research 19 (6), 1603-1611, 2013 | 25 | 2013 |
| Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer SA Brodie, G Li, D Harvey, FR Khuri, PM Vertino, JC Brandes Oncotarget 6 (31), 30773, 2015 | 16 | 2015 |
| Aberrant promoter methylation of caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC SA Brodie, C Lombardo, G Li, J Kowalski, K Gandhi, S You, FR Khuri, ... PLoS One 9 (9), e107124, 2014 | 14 | 2014 |
| Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer K Jung, JC Park, H Kang, JC Brandes Epidemiology and health 40, 2018 | 12 | 2018 |
Fadlo R. KhuriPresident and Professor, American University of BeirutVerified email at aub.edu.lb
